Identifying Uses for Immunotherapy Across Sarcoma Populations and Subtypes | CancerNetwork

Primary Results from the Phase 3 Leap-002 Study: Lenvatinib plus Pembrolizumab versus Lenvatinib as First-Line Therapy for Advanced Hepatocellular Carcinoma | OncLive

NICE recommends pembrolizumab for 1,600 more people with breast cancer - Cancer Research UK - Cancer News

🩷 Early-Stage Triple Negative Breast Cancer (TNBC) ✔️ Sa KEYNOTE-522, mas mataas ang pCR sa chemo pembrolizumab (~65%) kumpara sa chemo alone (~51%). ✔️ Mas bumaba ang risk ng recurrence at mas gumanda ang event-free survival. ✔️ Kung chemo lang ang kaya — effective pa rin ito. ✔️ Kung may residual disease, may dagdag na proteksyon ang capecitabine (CREATE-X trial). ✔️ Huwag kalimutan ang breast tissue marker bago chemo para mas accurate at safe ang breast-conserving surgery. 🩺 Hindi pare-pare

Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBC | OncLive

Watch Peter Schmid, MD, PhD, FRCP, of Barts Cancer Insitute discuss updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage #TNBC. https://www.onclive.com/view/dr-schmid-on-pembrolizumab-plus-chemotherapy-in-high-risk-early-stage-tnbc | OncLive